A pilot study of 40 women found that seven days of NAD+ supplementation produced 50% or greater reductions in hot flashes, bloating, and sleep disruption, alongside a measurable shift in estradiol-to-estrone balance. The findings suggest NAD+ metabolism influences estrogen dynamics during the menopause transition, though larger controlled trials are required to establish clinical significance.
Key Points
- NAD+ supplementation reduced menopausal symptoms by 50% within seven days
- Estradiol-to-estrone ratio shifted favorably in symptomatic participants
- Open-label design signals direction for future research, not clinical proof
Longevity Analysis
This research addresses a gap in longevity science by positioning menopause as a metabolic transition rather than solely a hormonal event. The speed of symptom improvement suggests that supporting cellular energy production and NAD+-dependent signaling may influence how reproductive hormones are metabolized and perceived by the body. If replicable in controlled settings, this work could reshape how practitioners approach symptom management during the menopause transition—moving from hormone replacement alone to metabolic support that restores balance across multiple signaling pathways.
Original published by Longevity.Technology, by Kyle Umipig.